Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Virtual Booth

    Contact Supplier

    Menu

    Alrizomadlin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Reveals Alrizomadlin Data at ASCO 2025
    Ascentage Pharma Reveals Alrizomadlin Data at ASCO 2025

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3092407/0/en/Live-from-ASCO-2025-Ascentage-Pharma-Releases-Promising-Clinical-Data-on-Alrizomadlin-Monotherapy-and-Combinations-in-Solid-Tumors.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Ascentage Pharma's Updated Results on Potential of Alrizomadlin + Pembrolizumab
    Ascentage Pharma's Updated Results on Potential of Alrizomadlin + Pembrolizumab

    06 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/asco-2022--ascentage-pharma-releases-updated-results-demonstrating-the-therapeutic-potential-of-alrizomadlin-apg-115-plus-pembrolizumab-in-patients-with-solid-tumors-who-progressed-on-immunotherapies-301562392.html

    PRNEWSWIRE
    06 Jun 2022
    Share Share
    Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted RPD Designation by FDA
    Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted RPD Designation by FDA

    21 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ascentage-pharmas-mdm2-p53-inhibitor-alrizomadlin-apg-115-granted-rare-pediatric-disease-designation-by-the-us-fda-for-the-treatment-of-neuroblastoma-301507249.html

    PRNEWSWIRE
    21 Mar 2022
    Share Share